Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 · kind B2 · utility
2Cited by
104References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2016 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | May 17, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.